{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:07:44Z","timestamp":1780524464003,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.02.068","type":"journal-article","created":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T06:45:22Z","timestamp":1394865922000},"page":"2722-2731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway"],"prefix":"10.1016","volume":"32","author":[{"given":"Johan","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Comandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oksnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"DeTora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique A.","family":"Caugant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.068_bib0005","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0010","series-title":"Vaccines","first-page":"399","article-title":"Meningoccal vaccines","author":"Granoff","year":"2008"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","article-title":"Development of natural immunity to Neisseria meningitidis","volume":"19","author":"Pollard","year":"2001","journal-title":"Vaccine"},{"issue":"Suppl 12","key":"10.1016\/j.vaccine.2014.02.068_bib0020","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0025","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.127.3.1011","article-title":"Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates","volume":"127","author":"Jennings","year":"1981","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis, Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines-an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0045","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.inf.0000202065.03366.0c","article-title":"Population-based analysis of meningococcal disease mortality in the United States: 1990\u20132002","volume":"25","author":"Sharip","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0065","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992\u20131996","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0070","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27","author":"Pace","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","article-title":"Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them","volume":"3","author":"Holst","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0080","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0085","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Holst Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0090","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0095","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0110","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0115","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0125","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0130","series-title":"16th international pathogenic Neisseria conference.","article-title":"Bivalent recombinant LP2086 vaccine to provide broad protection against","author":"Jansen","year":"2008"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0135","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/cpr.11.128","article-title":"Advances in meningococcal vaccines","volume":"9","author":"Pizza","year":"2012","journal-title":"Clin Pract"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0145","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erv.11.32","article-title":"A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"10","author":"Su","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0155","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0160","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0165","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0170","doi-asserted-by":"crossref","first-page":"B73","DOI":"10.1016\/j.vaccine.2011.12.061","article-title":"The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines","volume":"30","author":"Vogel","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/135.4.669","article-title":"Neisseria meningitidis infections in Northern Norway: an epidemic in 1974\u20131975 due mainly to group B organisms","volume":"135","author":"B\u00f8vre","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0180","first-page":"57","article-title":"The epidemiology of meningococcal disease in Norway 1975\u201391","volume":"14","author":"Lystad","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0185","first-page":"9","article-title":"Epidemiological patterns of meningococcal disease in Norway 1975\u20131979","volume":"3","author":"B\u00f8vre","year":"1980","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0190","first-page":"13","article-title":"Meningococcal disease in Norway 1981\u20131982, with focus on severe septicemia and death. Epidemiological trends and relation of cases to some health service factors","volume":"12","author":"B\u00f8vre","year":"1989","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0195","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/JCM.44.3.861-871.2006","article-title":"Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989","volume":"44","author":"Norheim","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0200","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0205","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/molbev\/msm092","article-title":"M.E.G.A4: Molecular evolutionary genetics analysis (MEGA) software version 4.0","volume":"24","author":"Tamura","year":"2007","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/bib\/bbn017","article-title":"MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences","volume":"9","author":"Kumar","year":"2008","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0215","series-title":"Molecular evolution an phylogenetics","author":"Nei","year":"2000"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0220","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0225","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2010.11.064","article-title":"Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1","volume":"29","author":"Brunelli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0230","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0235","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.vaccine.2009.12.082","article-title":"Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection","volume":"28","author":"Seib","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0240","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies","volume":"79","author":"Seib","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0245","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0250","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0255","first-page":"641","article-title":"Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers","volume":"132","author":"Caugant","year":"1986","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0260","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1073\/pnas.83.13.4927","article-title":"Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease","volume":"83","author":"Caugant","year":"1986","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0265","first-page":"139","article-title":"Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis","volume":"14","author":"Fr\u00f8holm","year":"1991","journal-title":"NIPH Ann"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.02.068_bib0270","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0275","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0280","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2008.12.052","article-title":"Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease","volume":"27","author":"Jacobsson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0285","first-page":"33","article-title":"Recent developments in vaccines to prevent meningococcal serogroup B infections","volume":"5","author":"Vermont","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0290","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0295","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0300","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0305","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2005.11.006","article-title":"Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens","volume":"24","author":"Jacobsson","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0310","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0315","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0320","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.4049\/jimmunol.178.7.4489","article-title":"Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal porin","volume":"178","author":"Madico","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0325","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0330","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/IAI.00849-10","article-title":"Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood","volume":"79","author":"Dunphy","year":"2011","journal-title":"Infect Immun"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2014.02.068_bib0335","doi-asserted-by":"crossref","first-page":"I40","DOI":"10.1016\/j.vaccine.2008.11.060","article-title":"Factor H and Neisserial pathogenesis","volume":"26","author":"Welsch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0340","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0345","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1042\/bj1930115","article-title":"The covalent-binding reaction of complement component C3","volume":"193","author":"Sim","year":"1981","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0350","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0355","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/CVI.00055-11","article-title":"Characterisation of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen, factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0360","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2013.06.009","article-title":"fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations","volume":"31","author":"Giuntini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.068_bib0365","series-title":"18th international pathogenic Neisseria conference, September 9\u201314","article-title":"Understanding the basis of anti-fHbp protective antibody provides new approaches for development of more effective second-generation meningococcal fHbp vaccines","author":"Granoff","year":"2012"},{"issue":"e00339-13","key":"10.1016\/j.vaccine.2014.02.068_bib0370","first-page":"1","article-title":"Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis","volume":"4","author":"Lewis","year":"2013","journal-title":"mBio"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T06:20:40Z","timestamp":1689056440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":74,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14002953"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}